Seelos Therapeutics Inc (SEEL)

[mean gene]

Fispemifene, imo was not a very good deal for Apricus because if it had good results they would not have the funds to market the product themselves. They would have to partner with someone and pay a royalty out of their royalty from the marketing company. Vitaros if approved in the U.S is a much better deal, they do not have to pay royalty out of their royalty unless Alergan opts out and they have to partner to market the product themselves. I wish they would not have taken their focus off Vitaros and not gotten involved with Fispemifene, I think we would not be in the mess we are in with the pps.